Cardiff Oncology, Inc.

NasdaqCM:CRDF Stock Report

Market Cap: US$240.3m

Cardiff Oncology Future Growth

Future criteria checks 2/6

Cardiff Oncology's earnings are forecast to decline at 20.7% per annum while its annual revenue is expected to grow at 59.5% per year. EPS is expected to decline by 6.7% per annum.

Key information

-20.7%

Earnings growth rate

-6.7%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate59.5%
Future return on equityn/a
Analyst coverage

Low

Last updated16 Dec 2024

Recent future growth updates

Recent updates

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Nov 07

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Oct 09
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 04

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Jun 19
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Earnings and Revenue Growth Forecasts

NasdaqCM:CRDF - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20270-98-78-883
12/31/20260-74-65-674
12/31/20250-56-51-485
12/31/20241-46-43-385
9/30/20241-43-35-35N/A
6/30/20241-41-32-32N/A
3/31/20241-40-31-30N/A
12/31/20230-41-31-31N/A
9/30/20230-41-34-33N/A
6/30/20230-40-33-33N/A
3/31/20230-39-33-32N/A
12/31/20220-39-35-34N/A
9/30/20220-39-33-32N/A
6/30/20220-38-30-30N/A
3/31/20220-34-28-27N/A
12/31/20210-28-23-23N/A
9/30/20210-25-21-21N/A
6/30/20210-23-19-19N/A
3/31/20210-24-19-19N/A
12/31/20200-23-17-16N/A
9/30/20200-20-15-14N/A
6/30/20200-20-14-14N/A
3/31/20200-17-13-13N/A
12/31/20190-17-13-13N/A
9/30/20190-17-14-14N/A
6/30/20190-16-14-14N/A
3/31/20190-19-14-14N/A
12/31/20180-19-13-13N/A
9/30/20180-18-13-13N/A
6/30/20181-18N/A-16N/A
3/31/20181-20N/A-17N/A
12/31/20171-25N/A-23N/A
9/30/20170-31N/A-29N/A
6/30/20170-37N/A-29N/A
3/31/20170-39N/A-33N/A
12/31/20160-39N/A-31N/A
9/30/20160-38N/A-29N/A
6/30/20160-31N/A-27N/A
3/31/20160-31N/A-24N/A
12/31/20150-27N/A-22N/A
9/30/20150-25N/A-19N/A
6/30/20150-27N/A-17N/A
3/31/20150-18N/A-15N/A
12/31/20140-14N/A-13N/A
9/30/20140-11N/A-11N/A
6/30/20140-10N/A-9N/A
3/31/20140-14N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRDF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRDF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRDF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRDF's revenue (59.5% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CRDF's revenue (59.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CRDF's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 02:37
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cardiff Oncology, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Sung Ji NamAvondale Partners
Bryan BrokmeierCantor Fitzgerald & Co.